Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

IncyteCARES is a program for residents of the United States and Puerto Rico.

IncyteCARES for OPZELURA:

Connecting Patients to Access, Reimbursement, Education,
and Support

Our mission is to help you understand your insurance coverage for OPZELURA and, if eligible, help you afford the cost of your prescription for OPZELURA. You can reach our team Monday through Friday,
8 AM–8 PM ET by calling 1-800-583-6964.

copay card

Copay Savings Program
for OPZELURA

With the copay savings card, eligible patients with commercial insurance may pay as little as $10* per tube for OPZELURA. The copay card may be used with refills, so be sure to save the copay card in a convenient location.

*Eligibility required. Individual savings limited to $2,076.50/tube, $10,000 per year. For use only with commercial insurance. The card may not be used if you are enrolled in a government-funded prescription insurance program or if you pay cash for your prescription. Must be used for an FDA-approved indication. Additional Terms and Conditions apply.

Get a Copay Savings Card

Answer a few questions, and you can be on your way to saving!

Eligible patients can receive their card immediately by choosing to download it or have it sent by email or text.

Activate a Copay
Savings Card

If you have a card provided by your doctor, it may need to be activated.
To activate your card, you’ll need to enter your member ID and answer a few questions to determine your eligibility.

Once activated, your card will be ready to use at the pharmacy.

For eligible patients only. See complete Terms and Conditions.

Other Financial
Assistance Options

hand cradling an Rx symbol

For Eligible Patients Who are Uninsured or Underinsured

IncyteCARES for OPZELURA Patient Assistance Program

Patients who are insured or underinsured may be eligible for free OPZELURA from Incyte.

To qualify, patients must:

  • Be enrolled in IncyteCARES for OPZELURA (if eligible)
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for OPZELURA for an FDA-approved use
  • Have an adjusted annual household income that is less than or equal to 400% of the Federal Poverty Level (FPL)

    The table below shows who might qualify for the Patient Assistance Program:

    If this many people live in your household:

    You may qualify if your full-year income before taxes is less than or equal to:

    $51,520

    $69,680

    $87,840

    $106,000

    $124,160

    If you live in Alaska or Hawaii or have a household with more than 5 members, please call 1-800-583-6964 to see if you may qualify. Income levels are subject to change on an annual basis; the numbers in this table are based on the 2021 Federal Poverty Level Guidelines.

  • Additional eligibility criteria depend on your insurance type:

You may qualify if you either:

  • Have no health insurance coverage at all
  • or

  • You have health insurance, but no coverage for prescription medicines

If you are enrolled in a Medicare Part D prescription insurance plan, you may qualify if:

  • You provided information that proves you can’t afford the cost or copay for OPZELURA
  • and

  • You are not covered by any government insurance or healthcare program, including but not limited to:
    • Medicaid
    • Veterans Affairs (VA)
    • Medicare Part D Low-Income Subsidy (LIS) program
    • Department of Defense (DoD)
    • TRICARE
    • Any State Patient Assistance Program (SPAP)
  • and

  • Your total out-of-pocket costs for OPZELURA are more than 10% of your household income

How to Apply

Ask your Healthcare Professional to start the program application by completing an IncyteCARES for OPZELURA Prescription and Enrollment form. You’ll both need to complete and sign certain parts of it. Or call IncyteCARES for OPZELURA at 1-800-583-6964, Monday through Friday, 8 AM–8 PM ET.

Terms and conditions apply. Terms of this program
may change at any time.

call center support

Contact Us

Call IncyteCARES for OPZELURA at 1-800-583-6964,
Monday through Friday,
8 AM–8 PM ET

INDICATION AND USAGE

OPZELURA is a prescription medicine used on the skin (topical) for short-term and non-continuous treatment of mild to moderate eczema (atopic dermatitis) in non-immunocompromised people 12 and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended.

The use of OPZELURA along with therapeutic biologics for atopic dermatitis, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION

OPZELURA cream is for use on the skin only. Do not use OPZELURA cream, in your eyes, mouth or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA cream contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death from all causes, including sudden cardiac death, has happened in people taking JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Some people have had lymphoma and other cancers while taking JAK inhibitors by mouth, especially if they are a current or past smoker. Some people have had skin cancers while taking OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA.

There is an increased risk of major cardiovascular events such as heart attack, stroke or cardiac death in people with cardiovascular risk factors and who are current or past smokers while using JAK inhibitors to treat inflammatory conditions.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have an infection that keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have or had TB, or have been in close contact with someone with TB
  • have had shingles (herpes zoster) or hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as:
    • fever, sweating, or chills
    • muscle aches
    • cough or shortness of breath
    • blood in your phlegm
    • weight loss
    • warm, red, or painful skin or sores on your body
    • diarrhea or stomach pain
    • burning when you urinate or urinating more often than usual
    • feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had blood clots in the veins of your legs or lungs in the past
  • have high cholesterol or triglycerides
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including:
    • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
    • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
    • pain or discomfort in your arms, back, neck, jaw, or stomach
    • shortness of breath with or without chest discomfort
    • breaking out in a cold sweat
    • nausea or vomiting
    • feeling lightheaded
    • weakness in one part or on one side of your body
    • slurred speech
  • Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing.
  • Tell your healthcare provider right away, if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath or fever

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsilitis), and runny nose (rhinorrhea).

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1 800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information and Medication Guide for OPZELURA.